Genomic Biomarkers Impact on Drug Discovery and Clinical Practice

Tuesday, January 27
7:00 - 8:00 AM Breakfast Chamisa
8:00 - 11:15 AM Sub-Typing Human Diseases Mesa A-B
Jeff Gulcher†, deCODE Genetics
Sub-Phenotyping CNS Diseases
David R. Cox, Perlegen Sciences, Inc.
Human Genetic Variation and Complex Human Traits
Daniel K. Burns, GlaxoSmithKline
Our Hands on SNP Experience
Peter Wagner, Zyomyx, Inc.
Molecular Profiling using Antibody Arrays
Grant Williams, US Food and Drug Administration
Overview of Opportunities and Issues
9:20 - 9:40 AM Coffee Break Promenade
3:30 - 4:30 PM Case Study Mesa A-B
Speaker to be Announced,
4:30 - 5:00 PM Coffee & Snacks Available Promenade
5:00 - 7:00 PM Emerging Methods for Genomic Biomarkers (Late Breaking News) Mesa A-B
Benjamin F. Cravatt III, The Scripps Research Institute
Activity-Based Protein Profiling - Chemical Strategies for Functional Proteomics
John K. Leighton, Center for Drug Evaluation and Research /Federal Drug Administration
Integration of Nonclinical Genomic Data into Safety Assessment
Speaker to be Announced,
7:00 - 8:00 PM Social Hour Mesa C

Wednesday, January 28
7:00 - 8:00 AM Breakfast Chamisa
8:00 - 9:00 AM Plenary Address Mesa A-B
Robert Temple, US Food and Drug Administration
What is the Same, What is Different with Genome Biomarkers?
9:00 AM - 11:00 PM Detection of Early Disease Mesa A-B
Emaneul F. Petricoin, US Food and Drug Administration
Proteomic Markers in Cancer
Sridhar Ramaswamy, Dana-Farber Cancer Institute
Genomic Approaches to Molecular Oncology
John Sninsky, Celera Diagnostica
Diagnostic Opportunities and Challenges for Biomarker Research
Penelope K. Manasco, First Genetic Trust
Protecting Patient confidentiality in Genetic Studies
9:20 - 9:40 AM Coffee Break Promenade
11:00 AM - 1:00 PM Poster Setup Mesa C
1:00 - 10:00 PM Poster Viewing Mesa C
4:30 - 5:00 PM Coffee & Snacks Available Promenade
5:00 - 7:00 PM Identifying Drug Responders From Non-Responders Mesa A-B
Nicholas C. Dracopoli, Bristol-Myers Squibb
Pharmacogenomic Applications in Preclinical and Clinical Drug Development
Eric Schadt, Rosetta Inpharmatics
Integrating Genetic and Functional Genomic Data to Predict Patient Response to Drug Treatment
Robert J. Meyer, Food and Drug Administration
Clinical Trial Design Considerations in Using Genomic Biomarkers of Safety and/or Efficacy
7:00 - 8:00 PM Social Hour Mesa C
8:00 - 10:00 PM Poster Session Mesa C

Thursday, January 29
7:00 - 8:00 AM Breakfast Chamisa
8:00 - 11:00 AM Biomarkers to Monitor the Safety of Compounds Mesa A-B
William D. Pennie, Pfizer, Inc
Title to be Determined
Roger G. Ulrich, Rosetta Inpharmatics Merck Research Laboratories
Molecular Profiling Approaches for Identifying Toxicological Pathways and Potential Biomarkers of Adverse Drug Effects
Urs A. Meyer, University of Basel
Diversity of Drug Response: From Genotype to Phenotype
James T. MacGregor, FDA National Center for Toxicological Research
Practical Aspects of Genomic Safety Biomarker Development
9:20 - 9:40 AM Coffee Break Promenade
3:30 - 4:30 PM Case Study Mesa A-B
Allen D. Roses, GlaxoSmithKline Genetics Research
Pharmacogenetics/Pharmacogenomics: View from a Pharmaceutical Pipeline
4:30 - 5:00 PM Coffee & Snacks Available Promenade
5:00 - 7:00 PM Developing a Strategy for Integrating Biomarkers into Clinical Practice Mesa A-B
Larry Norton, Memorial Sloan Kettering Cancer Center
Larry Lesko, US Food & Drug Administration
Stephen H. Friend, Merck & Company, Inc.
Charles W. Flexner†, Johns Hopkins University
7:00 - 8:00 PM Social Hour Mesa C
8:00 - 11:00 PM Entertainment Mesa C

Friday, January 30
Departure